Kos Pharmaceuticals Report issue

For profit Phase 4
Founded: Cranbury NJ United States (1988)
Status: Acquired by Abbott (2006)

Organization Overview

First Clinical Trial
2000
NCT00307307
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2005

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atherosclerosis (Phase 4)

Carotid Artery Diseases (Phase 4)

Coronary Artery Disease (Phase 4)

Coronary Disease (Phase 4)

Dyslipidemias (Phase 4)

Heart Diseases (Phase 4)

Hypercholesterolemia (Phase 3)

Hyperlipidemia, Familial Combined (Phase 4)

Hyperlipidemias (Phase 4)

Hyperlipoproteinemias (Phase 4)

Insulin Resistance (Phase 4)

Intermittent Claudication (Phase 3)

Metabolic Syndrome (Phase 4)

Myocardial Ischemia (Phase 4)

Peripheral Arterial Disease (Phase 3)

Peripheral Vascular Diseases (Phase 3)

Syndrome (Phase 4)

Vascular Diseases (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 10
  • # of Trial APIs: 9